Welcome to our dedicated page for Semler Scientific news (Ticker: SMLR), a resource for investors and traders seeking the latest updates and insights on Semler Scientific stock.
Semler Scientific, Inc. (Nasdaq: SMLR) generates news at the intersection of medical technology and digital assets. The company describes itself as a leader in medical devices and software to combat chronic diseases and as one of the leading corporate holders of Bitcoin. Its press releases and SEC filings highlight both developments in its healthcare business and updates on its Bitcoin treasury strategy.
On the healthcare side, Semler Scientific issues news about its flagship product QuantaFlo, an FDA-cleared, patented rapid point-of-care test that measures arterial blood flow in the extremities and aids in the diagnosis of cardiovascular diseases such as peripheral arterial disease. The company also reports on CardioVanta, Inc., its wholly owned subsidiary focused on early detection of heart failure and cardiac arrhythmia monitoring, which is intended to operate with a software-as-a-service model.
From a financial and corporate perspective, Semler Scientific’s news flow includes quarterly and annual financial results, details of its Bitcoin purchases and holdings, and performance metrics such as BTC Yield, BTC Gain and BTC $ Gain. Releases describe capital-raising activities through at-the-market equity offerings and convertible senior notes, as well as financing arrangements like a master loan agreement with Coinbase Credit Inc. collateralized by Bitcoin. The company also provides updates on legal and regulatory matters, including a civil investigative demand from the U.S. Department of Justice and an agreement in principle to settle related claims.
Recent disclosures also cover corporate governance and strategic transactions, such as board appointments, executive changes and the announced Agreement and Plan of Merger under which Semler Scientific would be acquired by Strive, Inc. in an all-stock transaction. Investors and observers who follow SMLR news can expect a mix of earnings announcements, Bitcoin strategy updates, healthcare product developments and merger-related communications.
Semler Scientific (SMLR) reported strong financial results for the year ended December 31, 2020. Revenues rose to $38.6 million, reflecting an 18% increase from $32.8 million in 2019. Pre-tax net income surged 54% to $16.5 million with a 43% margin. However, net income fell 7% to $14.0 million due to a prior year's tax benefit. The company’s cash position improved significantly, reaching $22.1 million. Looking to 2021, Semler anticipates continued profitability amid challenges posed by COVID-19 regulations.
Semler Scientific, Inc. (SMLR) announced its participation in the H.C. Wainwright Global Life Sciences Conference. CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg will present a company overview on March 9, 2021, accessible on-demand at semlerscientific.com/hcwr-global. Additionally, management will engage in one-on-one investor calls on March 10. Semler specializes in technology solutions for improving clinical effectiveness, focusing on chronic disease evaluation.
Semler Scientific, Inc. (OTCQB: SMLR) announced it will release financial results for Q4 and the full year ended December 31, 2020, on March 1, 2021, after U.S. markets close. CEO Doug Murphy-Chutorian will host a conference call at 4:30 PM ET the same day, joined by senior finance officials. Participants are encouraged to pre-register for immediate access to the call. Semler Scientific focuses on technology solutions that enhance healthcare provider effectiveness and efficiency and has received FDA clearance for its flagship product QuantaFlo®, aiding in diagnosing peripheral arterial disease.
Semler Scientific, Inc. (SMLR), based in San Jose, California, announced participation in several upcoming virtual investor conferences in September 2020. The events include the 5th Annual Colliers Securities Conference on September 10, the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 15, and the 4th Annual Best Ideas Growth (BIG4) Conference on September 17. The company focuses on improving healthcare efficiency with technology solutions, notably its QuantaFlo® product, which assists in diagnosing peripheral arterial disease.
Semler Scientific, Inc. (OTCQB: SMLR) announced the appointment of Daniel Messina to its Board of Directors effective August 13, 2020. With nearly 40 years of healthcare and technology experience, Messina brings valuable insights to the company. His prior roles include co-founder of HandsFree Health and leadership positions at West Corporation and Aetna Health. The Board now comprises four members, aiming to enhance strategic growth and the development of proprietary products for chronic disease evaluation.